2 weeks Ago By ABMN Staff
Alliancebernstein L.P. boosted its stake in Olema Pharmaceuticals, Inc.
( NASDAQ:OLMA – Free Report ) by 77.7% in the fourth quarter, HoldingsChannel.com reports.
The firm owned 313,982 shares of the company’s stock after buying an additional 137,319 shares during the period. Alliancebernstein L.P.
’s holdings in Olema Pharmaceuticals were worth $1,831,000 at the end of the most recent quarter. Several other large investors have also bought and sold shares of OLMA. Vanguard Group Inc.
increased its stake in shares of Olema Pharmaceuticals by 6.0% in the fourth quarter. Vanguard Group Inc.
now owns 2,685,009 shares of the company’s stock valued at $15,654,000 after buying an additional 152,117 shares during the period. State Street Corp increased its position in Olema Pharmaceuticals by 1.1% during the 3rd quarter.
State Street Corp now owns 1,969,963 shares of the company’s stock valued at $23,521,000 after purchasing an additional 21,986 shares during the period. Pictet Asset Management Holding SA raised its holdings in Olema Pharmaceuticals by 12.9% during the 4th quarter.
Pictet Asset Management Holding SA now owns 1,883,354 shares of the company’s stock worth $10,980,000 after purchasing an additional 215,895 shares during the last quarter. Candriam S.C.
A. lifted its position in shares of Olema Pharmaceuticals by 3.0% in the 4th quarter.
Candriam S.C.A.
now owns 1,551,562 shares of the company’s stock worth $9,046,000 after purchasing an additional 44,798 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Olema Pharmaceuticals by 52.1% in the 4th quarter.
Wellington Management Group LLP now owns 1,525,484 shares of the company’s stock valued at $8,839,000 after purchasing an additional 522,799 shares during the last quarter. 91.78% of the stock is owned by institutional investors.
Analyst Ratings Changes OLMA has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.
Oppenheimer reissued an “outperform” rating and issued a $25.00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.
Finally, JPMorgan Chase & Co. cut their target price on Olema Pharmaceuticals from $30.00 to $28.
00 and set an “overweight” rating on the stock in a research report on Friday, March 28th. Olema Pharmaceuticals Stock Up 3.8 % Olema Pharmaceuticals stock opened at $4.
42 on Friday. The company has a market capitalization of $302.03 million, a PE ratio of -2.
02 and a beta of 2.10. The firm’s fifty day moving average is $4.
21 and its 200 day moving average is $7.12. Olema Pharmaceuticals, Inc.
has a 12-month low of $2.86 and a 12-month high of $16.62.
Olema Pharmaceuticals ( NASDAQ:OLMA – Get Free Report ) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.
63) by $0.12. Sell-side analysts expect that Olema Pharmaceuticals, Inc.
will post -2.33 EPS for the current fiscal year. Olema Pharmaceuticals Profile ( Free Report ) Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. Further Reading Want to see what other hedge funds are holding OLMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc.
( NASDAQ:OLMA – Free Report ). Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
